Lipopolysaccharide-deficient acinetobacter baumannii shows altered signaling through host toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37

Infection and Immunity

Volumn 81, Issue 3, 2013, Pages 684-689

  Moffatt, Jennifer H ^a   Harper, Marina ^a   Mansell, Ashley ^a   Crane, Bethany ^a   Fitzsimons, Timothy C ^a   Nation, Roger L ^a   Li, Jian ^a   Adler, Ben ^a   Boyce, John D ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLISTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID A; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACINETOBACTER BAUMANNII; ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACINETOBACTER BAUMANNII; ANIMALS; CATHELICIDINS; CELL MEMBRANE; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MICE; MUTATION; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874729284     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01362-12     Document Type: Article

References (41)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
2. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5:939-951.
3. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
4. Hale JD, Hancock RE. 2007. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 5:951-959.
5. Gales AC, Jones RN, Sader HS. 2006. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gramnegative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect. 12:315-321.
6. Rodriguez CH, Karina B, Gabriela G, Marcela N, Carlos V, Angela F. 2009. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn. Microbiol. Infect. Dis. 65:188-191.
7. Park YK, Choi JY, Jung SI, Park KH, Lee H, Jung DS, Heo ST, Kim SW, Chang HH, Cheong HS, Chung DR, Peck KR, Song JH, Ko KS. 2009. Two distinct clones of carbapenem-resistant Acinetobacter baumannii isolates from Korean hospitals. Diagn. Microbiol. Infect. Dis. 64:389-395.
8. Medell M, Medell M, Martinez A, Valdes R. 2012. Characterization and sensitivity to antibiotics of bacteria isolated from the lower respiratory tract of ventilated patients hospitalized in intensive care units. Braz. J. Infect. Dis. 16:45-51.
9. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67:1607-1615.
10. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J. Antimicrob. Chemother. 66:2070-2074.
11. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St. Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54:4971-4977.
12. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. 2011. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55:3022-3024.
13. de Breij A, Dijkshoorn L, Lagendijk E, van der Meer J, Koster A, Bloemberg G, Wolterbeek R, van den Broek P, Nibbering P. 2010. Do biofilm formation and interactions with human cells explain the clinical success of Acinetobacter baumannii? PLoS One 5:e10732. doi:10.1371/journal.pone.0010732.
14. Renckens R, Roelofs JJ, Knapp S, de Vos AF, Florquin S, van der Poll T. 2006. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii pneumonia. J. Infect. Dis. 193:187-195.
15. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B. 2012. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3:e00312-12. doi:10.1128/mBio.00312-12.
16. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335-376.
17. Steeghs L, den Hartog R, den Boer A, Zomer B, Roholl P, van der Ley P. 1998. Meningitis bacterium is viable without endotoxin. Nature 392: 449-450.
18. Peng D, Hong W, Choudhury BP, Carlson RW, Gu XX. 2005. Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate. Infect. Immun. 73:7569-7577.
19. van der Ley P, Steeghs L. 2003. Lessons from an LPS-deficient Neisseria meningitidis mutant. J. Endotoxin Res. 9:124-128.
20. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9:847-856.
21. Hume DA, Underhill DM, Sweet MJ, Ozinsky AO, Liew FY, Aderem A. 2001. Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state. BMC Immunol. 2:11. doi:10.1186/1471-2172-2-11.
22. van Dijk A, Veldhuizen EJ, Kalkhove SI, Tjeerdsma-van Bokhoven JL, Romijn RA, Haagsman HP. 2007. The beta-defensin gallinacin-6 is expressed in the chicken digestive tract and has antimicrobial activity against food-borne pathogens. Antimicrob. Agents Chemother. 51:912-922.
23. Durr UH, Sudheendra US, Ramamoorthy A. 2006. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta 1758:1408-1425.
24. Sochacki KA, Barns KJ, Bucki R, Weisshaar JC. 2011. Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc. Natl. Acad. Sci. U. S. A. 108:E77-E81.
25. Qiu H, KuoLee R, Harris G, Chen W. 2009. High susceptibility to respiratory Acinetobacter baumannii infection in A/J. mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect. 11:946-955.
26. Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L, Tshimbalanga N, Akira S, van der Poll T. 2006. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am. J. Respir. Crit. Care Med. 173:122-129.
27. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, Ortiz C, Cobacho AR. 1996. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22:1026-1032.
28. Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL, Jacobs F. 2006. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. 25:257-260.
29. Pridmore AC, Wyllie DH, Abdillahi F, Steeghs L, van der Ley P, Dower SK, Read RC. 2001. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J. Infect. Dis. 183:89-96.
30. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, Moffatt JH, Nation RL, Li J, Harper M, Adler B, Boyce JD. 2012. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-beta-1,6-N-acetylglucosamine. Antimicrob. Agents Chemother. 56:59-69.
31. Ingalls RR, Lien E, Golenbock DT. 2000. Differential roles of TLR2 and TLR4 in the host response to Gram-negative bacteria: lessons from a lipopolysaccharide-deficient mutant of Neisseria meningitidis. J. Endotoxin Res. 6:411-415.
32. Steeghs L, de Cock H, Evers E, Zomer B, Tommassen J, van der Ley P. 2001. Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant. EMBO J. 20:6937-6945.
33. Murray GL, Attridge SR, Morona R. 2005. Inducible serum resistance in Salmonella typhimurium is dependent on wzzfepE-regulated very long O antigen chains. Microbes Infect. 7:1296-1304.
34. Hong M, Payne SM. 1997. Effect of mutations in Shigella flexneri chromosomal and plasmid-encoded lipopolysaccharide genes on invasion and serum resistance. Mol. Microbiol. 24:779-791.
35. Joiner KA. 1988. Complement evasion by bacteria and parasites. Annu. Rev. Microbiol. 42:201-230.
36. Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA. 2008. Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect. Immun. 76: 3577-3586.
37. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42:2206-2214.
38. Soon RL, Nation RL, Cockram S, Moffatt JH, Harper M, Adler B, Boyce JD, Larson I, Li J. 2011. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J. Antimicrob. Chemother. 66:126-133.
39. Cirioni O, Silvestri C, Ghiselli R, Orlando F, Riva A, Gabrielli E, Mocchegiani F, Cianforlini N, Trombettoni MM, Saba V, Scalise G, Giacometti A. 2009. Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. Crit. Care Med. 37:1403-1407.
40. Jiang Z, Vasil AI, Gera L, Vasil ML, Hodges RS. 2011. Rational design of α-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, 'specificity determinants,' total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chem. Biol. Drug Des. 77:225-240.
41. Vila-Farres X, Garcia de la Maria C, López-Rojas R, Pachón J, Giralt E, Vila J. 2012. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin. Microbiol. Infect. 18:383-387.